Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov 8:1:22-5.
doi: 10.1016/j.ebcr.2012.10.006. eCollection 2013.

Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review

Kenneth R Kaufman  1 , Arnaldo E Velez  2 , Stephen Wong  2 , Ram Mani  2
Affiliations

Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review

Kenneth R Kaufman et al. Epilepsy Behav Case Rep. .

Abstract

Lacosamide (LCM) is a novel antiepileptic drug (AED) approved by the FDA for adjunctive treatment of partial epilepsy with and without secondary generalization. Lacosamide dose-dependent dysrhythmias (PR-interval prolongation, AV block, and atrial fibrillation/flutter) have been reported. This case represents the first instance of LCM-induced atrial fibrillation following a low loading dose (200 mg). Risk factors for atrial fibrillation are addressed and discussed in the context of this case. Full cardiac history is recommended prior to patients being initiated on LCM. Cardiac monitoring may be required for at-risk patients on LCM. Clinicians need to be cognizant of this potential adverse effect.

Keywords: Atrial fibrillation; Cardiac adverse events; Complex partial status epilepticus; Education; Epilepsy; Lacosamide; Low dose; Video-EEG.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Initial routine EEG.
Fig. 2
Fig. 2
Seizure activity with sinus rhythm pre-lacosamide infusion.
Fig. 3
Fig. 3
Atrial fibrillation post-lacosamide infusion.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag. 2009;5:757–766. - PMC - PubMed
    1. Curia G., Biagini G., Perucca E., Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555–568. - PMC - PubMed
    1. Errington A.C., Stohr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73:157–169. - PubMed
    1. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308–1317. - PubMed
    1. Chung S., Sperling M.R., Biton V. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51(6):958–967. - PubMed

LinkOut - more resources